Name | Mianserin hydrochloride |
Description | Mianserin hydrochloride (Org GB 94) is a tetracyclic compound with antidepressant properties that blocks alpha-adrenergic, histamine H1, and certain serotonin receptors; it may cause drowsiness and hematological issues. |
In vitro | Mianserin dose-dependently elevates extracellular norepinephrine levels in the prefrontal cortex with minimal impact on the reuptake of norepinephrine in the rat cerebral cortex, due to its blockade of presynaptic inhibitory α2-adrenergic receptors and induction of regeneration-mediated release enhancement. In neonatal 6-OHDA-lesioned rats, mianserin attenuates the effects of SKF38393 and M-CPP, indicating that the actions of dopamine receptor agonists are mediated through the 5-HT neurochemical system. Additionally, in the medial prefrontal cortex of neonatal 6-OHDA-lesioned rats, 10 mg/kg S.C. Mianserin increased extracellular dopamine approximately 6-fold. |
In vivo | In elevated plus-maze experiments, Eltoprazine and Mianserin exhibit opposite effects: Eltoprazine induces anxiogenic-like behavior, while Mianserin triggers an anxiolytic-like response. Mianserin leads to a decreased number of these sites, whereas Eltoprazine results in an increase. Additionally, a subcutaneous dose of 2 mg/kg Mianserin produces a significant statistical increase in dopamine levels, exceeding 30% when compared to saline. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 99.7 mM DMSO : 4.23 mg/mL (14.06 mM), Sonication is recommended.
|
Keywords | Org GB94 | Mianserin hydrochloride | Inhibitor | inhibit | Mianserin Hydrochloride | Histamine Receptor | Org GB-94 | Mianserin |
Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Octopamine hydrochloride | Oxolinic acid | Alginic acid | Trazodone hydrochloride |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |